Jordi Bruix

Jefe de la Unidad

Featured publications

Featured Projects

  • A phase I open label, clinical trial evaluating the safety and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects with advanced hepatocellular carcinoma (HCC).

    Principal investigator: Jordi Bruix Tudo
    Funder: ADAPTIMMUNE
    Code: ADP-0033-001
    Duration: 01/01/2018 - 31/12/2033
  • Role and therapeutic potential of CPEB proteins in the transition from cirrhosis to hepatocellular carcinoma.

    Principal investigator: Jordi Bruix Tudo
    Funder: WORLDWIDE CANCER RESEARCH (FORMER AICR)
    Code: 16-0026_BRUIX
    Duration: 01/02/2016 - 31/12/2019
  • A prospective, multicentre, randomised, controlled study evaluating SIR-Spheres® Y-90 resin microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)

    Principal investigator: Jordi Bruix Tudo
    Funder: SIRTEX
    Code: SIRCCA
    Duration: 03/01/2016
  • Molecular regulation of the progression from hepatic steatosis to cirrhosis and hepatocellular carcinoma: Role and therapeutic potential of CPEB proteins.

    Principal investigator: Jordi Bruix Tudo
    Funder: ASOCIACIÓN ESPAÑOLA CONTRA EL CÁNCER
    Code: GCB15152955MEND
    Duration: 01/02/2015 - 31/12/2020
  • A Phase 1/2, Dose-escalation, Open-label Study of Nivolumab or Nivolumab in Combination with Other Agents in Advanced Hepatocellular Carcinoma Subjects with or without Chronic Viral Hepatitis

    Principal investigator: Jordi Bruix Tudo
    Funder: BRISTOL-MYERS SQUIBB
    Code: CA209040
    Duration: 01/02/2015